Evidence map›Paper›PMID 28785150›Full record

ArticleWorld journal of gastroenterology2017

Genetic polymorphisms predict response to anti-tumor necrosis factor treatment in Crohn's disease.

Uri Netz, Jane Victoria Carter, Maurice Robert Eichenberger, Gerald Wayne Dryden, Jianmin Pan, Shesh Nath Rai, Susan Galandiuk

Open access · hybridAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in World journal of gastroenterology, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 26 papers, 4 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
26citing papers in PubMed, 4 pooled it
2.9field-weighted citation impact, top 9% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

26 citing papers in PubMed, 4 syntheses or guidelines pooled it, 51 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Pooled it
  5. Article
  6. Article
  7. Review
  8. Article
  9. Review
  10. Precision medicine in inflammatory bowel disease.Precision clinical medicine · 2023
    Review
  11. Article
  12. Review
  13. Article
  14. Review
  15. Review
  16. Article
  17. Review
  18. Article
  19. Crohn's disease-related single nucleotide polymorphisms are associated with ileal pouch afferent limb stenosis.Journal of gastrointestinal surgery : official journal of the Society for Surgery of the Alimentary Tract · 2021
    Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 3 institutions in 2 countries.

Uri NetzUri Netz, Jane Victoria Carter, Maurice Robert Eichenberger, Susan Galandiuk, Price Institute of Surgical Research, the Hiram C. Polk Jr. MD Department of Surgery, University of Louisville School of Medicine, Louisville, KY 40202, United States.
Jane Victoria CarterUri Netz, Jane Victoria Carter, Maurice Robert Eichenberger, Susan Galandiuk, Price Institute of Surgical Research, the Hiram C. Polk Jr. MD Department of Surgery, University of Louisville School of Medicine, Louisville, KY 40202, United States.
Maurice Robert EichenbergerUri Netz, Jane Victoria Carter, Maurice Robert Eichenberger, Susan Galandiuk, Price Institute of Surgical Research, the Hiram C. Polk Jr. MD Department of Surgery, University of Louisville School of Medicine, Louisville, KY 40202, United States.
Gerald Wayne DrydenUri Netz, Jane Victoria Carter, Maurice Robert Eichenberger, Susan Galandiuk, Price Institute of Surgical Research, the Hiram C. Polk Jr. MD Department of Surgery, University of Louisville School of Medicine, Louisville, KY 40202, United States.
Jianmin PanUri Netz, Jane Victoria Carter, Maurice Robert Eichenberger, Susan Galandiuk, Price Institute of Surgical Research, the Hiram C. Polk Jr. MD Department of Surgery, University of Louisville School of Medicine, Louisville, KY 40202, United States.
Shesh Nath RaiUri Netz, Jane Victoria Carter, Maurice Robert Eichenberger, Susan Galandiuk, Price Institute of Surgical Research, the Hiram C. Polk Jr. MD Department of Surgery, University of Louisville School of Medicine, Louisville, KY 40202, United States.
Susan GalandiukUri Netz, Jane Victoria Carter, Maurice Robert Eichenberger, Susan Galandiuk, Price Institute of Surgical Research, the Hiram C. Polk Jr. MD Department of Surgery, University of Louisville School of Medicine, Louisville, KY 40202, United States.
Ben-Gurion University of the Negev · ILSoroka Medical Center · ILUniversity of Louisville · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

aimTo investigate genetic factors that might help define which Crohn's disease (CD) patients are likely to benefit from anti-tumor necrosis factor (TNF) therapy.

methodsThis was a prospective cohort study. Patients were recruited from a university digestive disease practice database. We included CD patients who received anti-TNF therapy, had available medical records (with information on treatment duration and efficacy) and who consented to participation. Patients with allergic reactions were excluded. Patients were grouped as ever-responders or non-responders. Genomic DNA was extracted from peripheral blood, and 7 single nucleotide polymorphisms (SNPs) were assessed. The main outcome measure (following exposure to the drug) was response to therapy. The patient genotypes were assessed as the predictors of outcome. Possible confounders and effect modifiers included age, gender, race, and socioeconomic status disease, as well as disease characteristics (such as Montreal criteria).

results121 patients were included. Twenty-one were non-responders, and 100 were ever-responders. Fas ligand SNP (rs763110) genotype frequencies, TNF gene -308 SNP (rs1800629) genotype frequencies, and their combination, were significantly different between groups on multivariable analysis controlling for Montreal disease behavior and perianal disease. The odds of a patient with a Fas ligand CC genotype being a non-responder were four-fold higher as compared to a TC or TT genotype (

conclusionThe Fas-ligand SNP and

Indexed as

AdalimumabAdultAllelesCertolizumab PegolColonoscopyCrohn DiseaseFas Ligand ProteinFemaleGastrointestinal AgentsGenotypeHumansInfliximabMaleMiddle AgedPolymorphism, Single NucleotideProspective StudiesAdalimumabCertolizumab PegolFASLG protein, humanFas Ligand ProteinGastrointestinal AgentsInfliximabTNF protein, humanTumor Necrosis Factor-alphaAntibodyAnti-tumor necrosis factorCrohn’s diseaseFas ligandGenotypeResponseSingle nucleotide polymorphismsTumor necrosis factor gene

Identifiers

PMID28785150
PMCPMC5526766
OpenAlexW2738098949

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.